Argos Therapeutics, Inc. (ARGS) Trading Down 1.1%
Argos Therapeutics, Inc. (NASDAQ:ARGS) dropped 1.1% on Friday . The stock traded as low as $0.17 and last traded at $0.18. Approximately 2,100,563 shares were traded during trading, a decline of 11% from the average daily volume of 2,360,670 shares. The stock had previously closed at $0.17.
Separately, Zacks Investment Research raised Argos Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating and three have issued a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $3.23.
The stock’s market cap is $9.55 million. The firm’s 50 day moving average is $0.22 and its 200-day moving average is $0.45.
Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. Argos Therapeutics had a negative net margin of 12,391.15% and a negative return on equity of 1,532.49%. The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.10 million. On average, analysts forecast that Argos Therapeutics, Inc. will post ($1.19) earnings per share for the current year.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.